Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Down 6.0% in January

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 139,100 shares, a decrease of 6.0% from the January 15th total of 148,000 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average trading volume of 13,200 shares, the days-to-cover ratio is presently 10.5 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. RODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EPRX. Raymond James Financial Inc. purchased a new position in Eupraxia Pharmaceuticals during the fourth quarter worth approximately $37,000. Millennium Management LLC purchased a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at $31,000. Finally, Bank of Montreal Can increased its stake in shares of Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after acquiring an additional 7,500 shares during the last quarter.

Eupraxia Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ EPRX opened at $3.33 on Wednesday. Eupraxia Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $5.33. The company has a 50-day moving average of $3.12 and a 200 day moving average of $2.89.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.